Showing results (51-60 of 72) with videos related to
Sort By:
Pageof 8
Current Oncology (Toronto, Ont.)|March 26, 2025
Enhancing CAR-T Efficacy in Large B-Cell Lymphoma with Radiation Bridging Therapy: A Real-World Single-Center ExperienceEva Laverdure, Luigina Mollica, Imran Ahmad, et al.Blood|January 22, 2024
CALR mutation burden in essential thrombocythemia and disease outcomePaola Guglielmelli, Natasha Szuber, Naseema Gangat, et al.Blood|April 15, 2020
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover studyGuillermo Garcia-Manero, Elizabeth A Griffiths, David P Steensma, et al.Journal of Medical Virology|October 21, 2021
Natural spring water gargle samples as an alternative to nasopharyngeal swabs for SARS-CoV-2 detection using a laboratory-developed testSarah Gobeille Paré, Julie Bestman-Smith, Judith Fafard, et al.British Journal of Haematology|September 12, 2023
Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) studyMaria Agustina Perusini, Igor Novitzky-Basso, Eshetu G Atenafu, et al.British Journal of Haematology|April 20, 2021
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trialDennis D H Kim, Igor Novitzky-Basso, Taehyung S Kim, et al.British Journal of Haematology|September 8, 2021
BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phaseDennis Dong Hwan Kim, Taehyung Simon Kim, Eshetu G Atenafu, et al.Blood|April 18, 2014
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesisRaajit Rampal, Fatima Al-Shahrour, Omar Abdel-Wahab, et al.Mayo Clinic Proceedings|March 3, 2019
3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease SubgroupsNatasha Szuber, Mythri Mudireddy, Maura Nicolosi, et al.Nature Genetics|September 25, 2012
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesisLambert Busque, Jay P Patel, Maria E Figueroa, et al.Pageof 8